Under the global exclusive license deal, Kumquat will be responsible for the Phase 1a study of its inhibitor and Bayer will ...

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...

BERLIN (Reuters) -German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat ...

Bayer has inked a global licensing deal with Kumquat Biosciences for a KRAS G12D cancer drug, allowing Phase 1a trials to be ...

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

Bayer & Kumquat Biosciences enter global license and collaboration to develop and commercialize Kumquat’s KRAS G12D inhibitor: Berlin, Germany Wednesday, August 13, 2025, 11:00 ...

For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...

Bayer and Kumquat Biosciences have signed an exclusive global license and collaboration to develop a KRAS G12D inhibitor, ...

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.